Pharmaceuticals News & Press Release Distribution

The China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers

ROCKVILLE, Md. and SUZHOU, China, Oct. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and o...

2022-10-10 08:23 2500

The China NMPA Approved CYRAMZA® (ramucirumab) for the Treatment in Patients with Hepatocellular Carcinoma

ROCKVILLE, Md. and SUZHOU, China, Oct. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and o...

2022-10-10 08:20 2009

Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19

--The multiple-dose escalation Phase I clinical trial will enroll 72 healthy subjects including 60 subjects in 6 dose escalation cohorts and 12 subjects in food effect trial. The enrollment is expected to be completed in the fourth quarter of 2022 --ASC10 is an oral double prodrug. After oral ...

2022-10-10 08:10 1725

Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an oral small molecule GLP-1 receptor agonist for the Treatment of Obesity and Type 2 Diabetes

HANGZHOU, China and SAN FRANCISCO, Oct. 10, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today the initiation of dosing in a Phase 1 clinical trial ev...

2022-10-10 08:00 1945

WuXi Biologics Co., Ltd. Removed from Unverified List

WUXI, China, Oct. 10, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics Co., Ltd. located in Wuxi city was removed from the Unverified List (UVL) by the U....

2022-10-10 07:55 3131

Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting

* Oral presentation highlights preclinical data of ATG-031, an in-house discovered anti-CD24 monoclonal antibody * Three poster presentations showcase preclinical data of ATG-101, a PD-L1/4-1BB bispecific antibody developed in-house, ATG-018, an ATR inhibitor discovered in-house, and ATG-027,...

2022-10-08 10:43 1928

Everest Medicines Announces Approval of XERAVA® in Hong Kong for the Treatment of Complicated Intra-Abdominal Infections

SHANGHAI, Oct. 8, 2022 /PRNewswire/ -- Everest Medicines Limited (HKEX 1952.HK, "Everest Medicines", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, annou...

2022-10-08 08:00 2367

First patient treated in Clarity's therapeutic prostate cancer trial

Highlights * Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)[1] investigating Targeted Copper Theranostics (TCTs) in patients with metastatic castrate-resistant prostate cancer (mCRPC) ...

2022-10-07 21:06 1628

Synapse Medicine Initiates Multi-Site Implementation Study with Leading U.S Hospitals

* Synapse Medicine clinical decision support technology analyzes drug-related risks based on each patient's clinical characteristics and will be studied for its impact on inpatient pharmacist efficacy and efficiency. * The Synapse Medicine medication reconciliation tool will be deployed throu...

2022-10-07 07:05 1791

TauRx Announces Results from Phase 3 Alzheimer's Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions

* For people with early Alzheimer's (MCI), HMTM treatment resulted in sustained improvement in cognition over pre-treatment baseline, and normalisation of brain atrophy to a rate similar to healthy individuals * For people with mild to moderate Alzheimer's, HMTM stabilised cognition and funct...

2022-10-06 18:00 1603

Cytiva strengthens cell line development with CEVEC acquisition

* Viral vector manufacturing and cell line development are keystone technologies in the making of gene therapies * 46 scientific experts based in Cologne, Germany, join the Cytiva team in the genomic medicine space * Cytiva customers will have immediate access to technologies that solve som...

2022-10-06 14:00 1612

Servier unveils its 2030 ambition and reveals a new visual identity

* A new ambition by 2030 to accelerate its transformation dynamic * A visual identity, a marker of the successful transformation of the Group, its ambitions and its renewal PARIS, Oct. 6, 2022 /PRNewswire/ -- Servier today unveils its 2030 ambition as well as a new visual identity that reflec...

2022-10-06 13:30 1808

ASTRAZENECA, First Organization in Egypt receiving Best place to work for Millennials Award

CAIRO, Oct. 5, 2022 /PRNewswire/ -- AstraZeneca Egypt, was recently certified as a Best Place to Work for Millennials marking it the first organization in Egypt to receive such award. The certification is based on an HR analysis of the company policies focusing on Millennials and an anonymous emp...

2022-10-05 22:59 1022

Ascletis Announces Dosing of the First Patient in Phase II Clinical Trial of THRβ Agonist ASC41 for 52-Week Treatment of Liver Biopsy-Proven NASH

-- ASC41 is ranking first in China and third in the world in terms of clinical progress as a thyroid hormone receptor β (THRβ) agonist drug candidate for non-alcoholic steatohepatitis (NASH). ASC41 Phase II clinical trial is currently the most advanced 52-week Phase II clinical trial which is in...

2022-10-05 08:10 2223

Transcenta Received IND Clearance from FDA for Its Best-In-Class MASP2 Targeting Antibody TST004 for the Treatment of IgA Nephropathy

SUZHOU, China, Oct. 5, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that TST004, its best...

2022-10-05 08:00 1983

HAVAS HEALTH & YOU APPOINTS PAUL PFLEIDERER AS PRESIDENT OF HAVAS LIFE NEW YORK

NEW YORK, Oct. 4, 2022 /PRNewswire/ -- As the rapid evolution of the health and wellness sector continues to necessitate innovative thinking and activation across the industry, Havas Health & You today announced that it has appointed seasoned strategic leaderPaul Pfleiderer as President of Havas ...

2022-10-04 21:00 1031

HanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner

* Immunovant, a HanAll's licensed partner, unveiled its plan to develop a new FcRn inhibitor, HL161ANS (also known as IMVT-1402) * In animal studies, HL161ANS indicated deep IgG reductions similar to batoclimab with no or minimal impact on albumin and LDL cholesterol level * Batoclimab (form...

2022-10-04 19:00 1202

Hayashibara Brings Back "Trehalose Symposium" to Reveal Its Game-changing Versatilities in Human Biochemistry

OKAYAMA, Japan, Oct. 4, 2022 /PRNewswire/ -- Hayashibara Co., Ltd., a member of Nagase Group and headquartered in Okayama City, westernJapan, hosted the 24th Trehalose Symposium, with the support of the Japanese Society of Applied Glycoscience, onSeptember 8, 2022. Photo: https://kyodonewsprwir...

2022-10-04 14:00 1001

DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY

Debiopharm awards the winning scientists for the JCA (Japanese Cancer Association) Award for innovative, disruptive, and translational oncology research LAUSANNE, Switzerland, Oct. 3, 2022 /PRNewswire/ -- Debiopharm ( www.debiopharm.com ), a Swiss-based global bioph...

2022-10-03 15:00 1359

AeroRx Partners with HCmed to Develop a Nebulized LABA/LAMA Combination Solution for the Treatment of Chronic Obstructive Pulmonary Disease

TAIPEI, Oct. 2, 2022 /PRNewswire/ -- AeroRx Therapeutics, LLC. (AeroRx) and HCmed Innovations Co., Ltd. (HCmed) have initiated a collaboration, introducing a LABA/LAMA combination solution for delivery with a breath-actuated nebulizer. This collaboration sets forth the framework by which both com...

2022-10-03 09:00 1035